ArtVentive Medical Group, Inc. Announces Addition To European Sales Management Team

CARLSBAD, CA--(Marketwired - September 10, 2014) - ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today the addition of Henk van der Laak to its sales management team as Director of Sales for Europe.

“We are very excited to welcome Henk to our expanding global team,” said Jim Graham, Chief Executive Officer of ArtVentive Medical. “This critical position will address the demands of our growing business, allowing us to provide additional clinical support, training and other resources to our current and future distribution partners throughout the European markets.”

Mr. van der Laak will lead the European sales efforts for the Company’s EOS™ Peripheral Vascular Occlusion System in coordination with distributors across Europe. With a strong track record of success, Henk van der Laak brings extensive experience to his new role. He was most recently with Hemocue AB, a producer of diagnostic testing devices for the healthcare industry, and previously served in European sales leadership roles with both SenoRx, Inc. and the Cordis Corporation, a Johnson and Johnson Company.

The Company is now shipping an expanding range of ArtVentive EOS™ device sizes to its growing European distribution network and is preparing to launch into the North American market following the receipt of regulatory approval.

The Company also announced that it would exhibit at the upcoming Cardiovascular and Interventional Radiology Society of Europe (CIRSE) conference to be held September 13th through the 16th in Glasgow, Scotland. Dr. Leon Rudakov, President of ArtVentive, stated, “As one of the world’s largest Interventional Radiology congresses, CIRSE provides an optimal venue to discuss the EOS™ unique platform and share information from the recent successful clinical results in conjunction with ArtVentive’s EOS™ post-market surveillance studies in Switzerland, Belgium and Poland.”

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™.

The ArtVentive EOS™ is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network. The ArtVentive EOS™ is designed to serve as a safe and reliable alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant health issues.

The ArtVentive EOS™ serves as a proprietary technology platform for several major clinical areas, including peripheral and neurological vascular disorders, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.

More information about ArtVentive can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company’s ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.